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Abstract
Culture-independent microbiological technologies that interrogate complex microbial populations
without prior axenic culture, coupled with high-throughput DNA sequencing, have revolutionized
the scale, speed, and economics of microbial ecological studies. Their application to the medical
realm has lead to a highly productive merger of clinical, experimental, and environmental
microbiology. The functional roles played by members of the human microbiota are being actively
explored through experimental manipulation of animal model systems and studies of human
populations. In concert, these studies have appreciably expanded our understanding of the
composition and dynamics of human-associated microbial communities (microbiota). Of note,
several human diseases have been linked to alterations in the composition of resident microbial
communities, so-called dysbiosis [1]. However, how changes in microbial communities contribute
to disease etiology remains poorly defined. Correlation of microbial composition represents
integration of only two datasets (phenotype and microbial composition). This article explores
strategies for merging the human microbiome data with multiple additional datasets (e.g. host
single nucleotide polymorphisms [SNP] and host gene expression) and for integrating patient-
based data with results from experimental animal models to gain deeper understanding of how
host-microbe interactions impact disease.
Dysbiosis and disease etiology
Human-associated microbial communities, particularly those of the gastrointestinal (GI)
tract, provide myriad beneficial services to ourselves. For instance, gut microbes transform
otherwise indigestible plant polysaccharides into absorbable short-chain fatty acids (SCFA)
© 2011 Elsevier Ltd. All rights reserved.
Corresponding author: Frank, D.N. (daniel.frank@ucdenver.edu).
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
NIH Public Access
Author Manuscript
Trends Microbiol. Author manuscript; available in PMC 2012 September 1.
Published in final edited form as:













[2] and participate in the development and maintenance of immune homeostasis [3, 4].
Disruption of any of these mutualistic relationships through shifts in microbial community
composition (i.e. dysbiosis [1]) could compromise human health and contribute to disease
onset, progression, or duration. Indeed, recent applications of culture-independent
sequencing technologies to studies of human health and disease have revealed dysbioses
associated with diverse conditions, including antibiotic-associated diarrhea [5, 6], bacterial
vaginosis [7–9], celiac disease [10], colorectal cancer [11, 12], cystic fibrosis [13, 14],
esophageal disease [15], Crohn’s disease and ulcerative colitis (collectively referred to as
inflammatory bowel diseases [IBD]) [16–22], irritable bowl syndrome [23–26], necrotizing
enterocolitis [27], non-bacterial prostatitis [28, 29], pre-term birth [30], obesity [31–33],
pouchitis [34–36], and psoriasis [37].
What has been lacking in studies of human dysbioses is determination of the biological and
clinical significance of these community imbalances. Are the changes in enteric microbiota
that are observed in IBD simply a consequence of chronic inflammation and its treatment or
are they necessary determinants of initiation and/or perpetuation of pathogenesis? Figure 1
presents four possible causal relationships between disease and dysbiosis. First, dysbiosis
could be a primary trigger that leads to pathogenesis (Figure 1, Path A). Although the initial
factors that disrupt the commensal microbiota are not well defined, their effects are
mediated through induction of detrimental immune responses or compromised mucosal
barrier function. For example, depletion of commensal bacteria can lead to increased
populations of potentially pathogenic organisms, such as occurs with toxin-secreting
Clostridium difficile proliferation following antibiotic treatment [6]. Restoring the normal
microbiota would, in this scenario, be expected to lessen pathogenesis. Second, dysbiosis
could arise in parallel with pathogenesis (Figure 1, Path B), but not serve as a causal factor
of disease. In this case, treating the dysbiosis would not ameliorate disease. Similarly
(Figure 1, Path C), the pathological condition itself, or its treatment, could cause a secondary
shift in microbial community structure. For example, remodeling of the intestinal mucosal
milieu following prolonged inflammation could significantly alter both the intestinal
environment and the microbial inhabitants of this niche. Finally, even if not a primary cause
of disease (Figure 1, Path D), disruption of the commensal microbial community and the
mutualistic functions it contributes to the host could contribute to the duration or severity of
a disease state. For example, imbalances in the microbiota could also lead to metabolic
alterations (e.g. decrease in luminal SCFA) that in turn compromise the protective functions
of the epithelial barrier [38]. Alternatively, these abnormal bacteria could secondarily invade
a disrupted mucosal barrier or provide antigens and Toll-like receptor ligands that further
stimulate adaptive and innate immune responses thereby augmenting and perpetuating an
ongoing inflammatory response [39–41]. In these situations, remediating the dysbiosis
should provide palliative relief, but likely would not effect a cure, if the primary etiological
factor(s) are not addressed. That many of the syndromes associated with dysbiosis are
chronic suggests that loss of the normal functions provided by a commensal community,
even if not the ultimate causative agent, could significantly prolong the disease state and
complicate its resolution.
Delineating the causes and etiological consequences of disease-associated dysbioses remains
a crucial challenge in studies of the human microbiota. As with other diseases of uncertain
microbial etiology, fulfilling Koch’s postulates in the context of dysbiosis is problematic.
First, Koch’s postulates are predicated on the establishment of a parasitic relationship
between the host and etiologic agent, whereas some dysbiosis-associated pathologies might
instead arise from loss of mutualistic interactions. Second, whereas the defining feature of
Koch’s postulates is the demand for isolation of a single pathogen in pure culture, dysbiosis
is by definition a community phenomenon. The causal significance of dysbiosis could
instead be more effectively evaluated through modifications of Koch’s postulates that have
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been set forth in the era of risk-factor epidemiology (e.g. those of Hill [42] and Evans [43])
and molecular microbiology (e.g. those of Fredricks and Relman [44]). These guidelines
recognize that a constellation of necessary, but not sufficient, causal relationships often is
the hallmark of diseases that are chronic, multi-factorial, and/or develop with long latencies.
Moreover, the Fredricks-Relman guidelines embrace the utility of molecular-based
technologies for detecting microorganisms in the absence of culture, a key feature given that
syntrophic and symbiotic relationships among microbial community members are likely to
limit the reductionist approach of axenic culture. Thus, the pathogenic capacity of a
microbial community as a whole could be examined in the context of these revised criteria.
In evaluating causal relationships, both Hill’s criteria and the Fredricks-Relman guidelines
consider the strength, consistency, and specificity of association between the occurrence of a
putative pathogen and a disease, as well as their dose-response relationship. The degree to
which these criteria are satisfied typically provides the primary evidence in support of a
proposed association between dysbiosis and disease (e.g. [16]). Hill’s criterion of biological
plausibility, though not emphasized by the author [42], is supported in the case of dysbiosis
by continuing, intensive work on the biochemical, physiological, immunological, and
genetic bases of host-microbiota interactions [40, 41, 45–49]. However critical to
establishing correlations, these criteria would not necessarily differentiate among the causal
relationships outlined in Figure 1.
Our contention is that three additional Hill’s criteria – namely the coherence, temporality,
and experimental support for causality – are the critical factors required to understand the
causal role of dysbiosis. Coherence relates to the fit between a hypothesized dysbiosis-
disease causal relationship and all other knowledge concerning the disease. This is
essentially a hypothesis generating approach to determining the relationship between
dysbiosis and disease. The challenge in patient based research is that the number of potential
variables (genetic and environmental factors) to consider is extremely large compared with
the number of samples that can be analyzed. Addressing temporality could require
prospective collection of samples prior to the onset of disease (e.g. longitudinal follow-up of
unaffected relatives of patients). The generation of genetic experimental animal models
provides extremely useful tools for testing causality. However, differences between the
experimental animal model and humans present a potential challenge. The ultimate goal of
these strands of research is to determine whether (i) there are interventions that will alter
dysbiosis and (ii) whether these interventions alter the course of the disease. The following
sections describe these criteria in greater detail, as exemplified by an interdependent
approach to delineate the role of dysbiosis in human IBD.
Coherence: integration of the microbiome and human genomics/post-
genomic data
Determining whether enteric dysbiosis modifies the incidence and progression of IBD will
require integration and correlation of large-scale surveys of microbial communities with
rigorously characterized human genotypes and molecular phenotypes (microarray data,
proteomic data, and histologic imaging data) in both Crohn’s disease and non-Crohn’s
disease cohorts (Figure 2). Moreover, collection of a very large number of well phenotyped
clinical specimens is necessary to accurately link potentially subtle patterns of altered
enteric microbiota with host response and disease occurrence. Subsequent mechanistic
studies in animal models, including selective colonization of gnotobiotic mice with bacterial
species identified by the broad human surveys, combined with targeted in vitro experiments
can determine causal relationships and further define mechanisms of action.
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The observation that a subset of IBD patients harbor abnormal enteric microbiota, while the
microbiota of other IBD patients are apparently ‘normal’ raises several questions [16]. First,
do these differences persist within an individual or do all IBD patients experience periodic
flares of dysbiosis? Does dysbiosis arise from prolonged treatment with antibiotics or other
agents that could alter the microbial habitat of the intestinal tract? Do host genetics,
particularly the presence of IBD risk alleles affect the incidence or prevalence of dysbiosis
in individuals, regardless of disease state? The correlation of abnormal microbiota with a
younger age of surgery [16] was intriguing because alleles of NOD2/CARD15 and ATG16L1
that increase the risk of Crohn’s disease also are associated with younger age of surgery.
Host genetic factors that affect innate immunity, such as the NOD2 and ATG16L1 genes,
could affect microbial composition, particularly in the ileum. The three prevalent risk alleles
of NOD2 (Leu1007fs, R702W, and G908R) are associated with the highest relative risks of
ileal Crohn’s disease among the ~100 IBD susceptibility loci identified thus far.
To determine whether human genetic factors are associated with dysbiosis, NOD2 and
ATG16L1 genotypic data were integrated with a previously published 16S rRNA sequence
dataset [16]. This analysis revealed associations between alterations in intestine-associated
microbial composition and disease phenotype, NOD2, and ATG16L1 genotype [22].
Analysis of an independent set of disease unaffected ileum samples collected from patients
with three non-overlapping IBD phenotypes undergoing initial surgery: (i) ileal Crohn’s
disease, (ii) isolated colitis, and (iii) non-IBD controls. Multivariate analysis of the 16S
rRNA sequence dataset selected disease phenotype, C. difficile, and NOD2 genotype as
significantly associated with shifts in grossly unaffected ileum-associated microbial
composition. In these analyses, potential confounding variables such as obesity and IBD
medications were also included. Disease phenotype and NOD2 genotype were also selected
as significantly associated with shifts in the relative abundance of the Clostridium
coccoides-Eubacterium rectales group measured by PCR.
Thus, NOD2 and ATG16L1 alleles have determining effects on the microbiota that are
independent of the occurrence of overt disease. An important implication of this result is that
the dysbiosis that has been widely reported in connection with Crohn’s disease [17] is not
solely the result of environmental effects such as treatment history or diet. Interestingly, the
abundance of an individual enteric genus is rarely significantly correlated with both NOD2
and ATG16L1 genotype, suggesting complex interactions between host genotype and
microbial community composition [22]. Moreover, several genera are significantly
associated with disease phenotype, but not with NOD2 or ATG16L1 genotype, suggesting
either that disease itself influenced the relative frequencies of these genera or that other
genetic determinants were involved. Therefore, further associations between other Crohn’s
disease polymorphisms and environmental factors likely will emerge as study populations
expand.
An association between enteric microbial profiles and genetic predisposition suggests that
dysbiosis arises either as a consequence of direct genetic effects on microbial composition,
perhaps through altered Paneth cell function [50–52] or as a direct result of the pathogenic
process. Thus, the question of whether dysbiosis contributes to Crohn’s disease pathogenesis
or is an innocuous byproduct remains to be settled. Furthermore, how mucosal barrier
dysfunction or inflammation per se could lead to dysbiosis also is not clear. The plethora of
luminal commensal bacteria are largely tolerated by the mucosal immune system and
ignored by the systemic immune systems of normal hosts [49, 53, 54], but are essential
drivers of pathogenic mucosal and systemic inflammatory responses in genetically
predisposed hosts [39–41, 55]. Enteric microbial communities play a critical role in this
process by stimulating the development of GI lymphoid tissues [56, 57], fortifying the
physical epithelial barrier [58], and regulating the quality and magnitude of the mucosal
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immune response [3, 4] to commensal bacteria and potential pathogens. Shifts in microbial
community composition that arise from dysfunctional innate mucosal immunity suggest a
selective disadvantage to those microbial groups that serve to nurture gut barrier integrity.
To fully understand the mechanism(s) by which host genetic factors influence microbial
composition and the functional consequences of the changes in microbial composition it is
critical that the microbiome data be linked also with host and bacterial transcriptomics [59,
60], proteomics [61–63], and metabolomics [64–66].
Experimental support: human interventions and animal models
The strongest evidence that dysbiosis contributes to human disease could be obtained
through double-blind, randomized controlled experiments with agents that normalize
dysbiotic profiles in individuals with disease or create dysbiosis in normal individuals.
Under these conditions, the causal relations between exposure to dysbiosis and subsequent
development of pathology then can be defined. However, ethical and practical
considerations (how to artificially create a dysbiosis that precisely matches that of a
particular disease, how to sustain microbial alterations with antibiotics, probiotics and
prebiotics and how to reproduce environmental triggers that likely initiate inflammatory
processes [40, 52]) limit this approach. Consequently, quasi-experimental studies in which
dysbiosis is induced as a consequence of medical (e.g. C. difficile-associated diarrhea
resulting from antibiotic exposure[6]) or surgical procedures (e.g. pouchitis following ileal-
pouch anal anastomosis [34]) likely will be the dominant means of manipulating human
microbiota prior to disease occurrence.
In parallel with quasi-experimental studies of humans, well-designed direct experiments
with animal models of disease can contribute important insights into the timing and
mechanistic basis of disease pathophysiology in relation to altered microbiota [67]. Multiple
models of experimental colitis exhibit dysbiosis similar to that seen in human IBD, with
contraction of several Clostridium subsets and expansion of Enterobacteriaceae, including
Escherichia coli [68, 69]. Studies in gnotobiotic mice and rats implicate commensal enteric
bacteria in the pathogenesis of immune-mediated chronic intestinal inflammation [67, 70,
71] and demonstrate that individual bacterial species relevant to the dysbiosis of human IBD
have differential abilities to induce or prevent experimental enterocolitis [70, 72]. Of note
however, not all species that are altered in abundance in experimental colitis can elicit
pathogenesis, whereas those that are sufficient to cause colitis may not be affected by
disease state [67]. Therefore, dysbiosis might best be viewed as a starting point for careful
experimentation, rather than an endpoint.
Host genetic background is a determinant both of enteric bacterial profiles and inflammatory
sequellae to individual bacterial species. For example, NOD2-deficient mice display altered
mucosally-associated bacteria and Bacteroides spp. composition in this model [73]. These
differences were not, however, detected in a comparison of fecal microbiota, suggesting that
the effect of NOD2 deficiency on microbial composition was restricted to the ileum, and
perhaps reflect changes in mucosa-adherent communities [73]. Similarly, germ-free (sterile)
IL-10 deficient mice develop proximal colitis when mono-colonized with either several
adherent/invasive E. coli strains, including one human ileal Crohn’s disease isolate, and
aggressive distal colitis and duodenal inflammation when selectively colonized with
Enterococcus faecalis, but no disease with Bacteroides vulgatus [72].
Both traditional probiotic bacterial species (Lactobacillus spp. and Bifidobacterium spp.) as
well as a commensal species that is decreased in human Crohn’s disease (Faecalibacterium
prausnitzii) can attenuate experimental colitis [17]. Reports of transmission of colitis [74,
75], obesity [76], and metabolic syndrome [77] by fecal transfer to normal recipients
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strongly implicate dysbiosis as a primary etiologic factor in disease pathogenesis, although
secondary changes in luminal microbiota following nonspecific intestinal inflammation or
injury have been documented. An exciting observation that a common enteric viral
pathogen, norovirus, can induce functional and phenotypic alterations in mice with
decreased ATG16L1 expression offers proof of principle that environmental triggers can
modulate genetically-defined disease susceptibility [52]. Recent evidence that human fecal
microbial composition can be conserved in gnotobiotic mouse recipients provides an elegant
opportunity to explore the pathogenicity of dysbiotic bacteria in human IBD patients in
murine models [78]. These selective constitution studies will help define mechanisms of the
pathogenicity of human bacterial profiles and microbial subsets in recipients by modeling
interactions of human genes, environmental stimuli and human microbiota.
Temporality: modeling causal relationships in a systems biological
framework
In addition to experimental animal and human microbial manipulation approaches,
longitudinal observational studies represent a critical means of assessing the causal
relationship between dysbiosis and disease occurrence. In principle, these studies would
determine whether a particular exposure (e.g. alterations in microbiota) precedes
development of overt disease. Despite their clear utility, few if any such trials have been
conducted to date, although technological innovations in studying human microbiota now
make large-scale cohort and/or case-control studies feasible. However, the chronic nature
and the protracted preclinical phase of many dysbiosis-associated diseases could complicate
interpretation of results, because timing of disease onset is imprecise in these cases,
especially when human genetic loci help determine disease susceptibility.
Although the technology of culture-independent metagenomics is well established,
development of statistical tools for analyzing microbial community organization has lagged
behind the evolution of DNA sequencing technologies. An important component of this
work will be continued development of computational and statistical methods for analysis of
host-microbe dynamics. Moreover, robust methods are needed to integrate and mine data
generated through myriad ‘omics technologies. As Sauer et al. have noted in regards to
genetic analysis "The (traditional) reductionist approach has successfully identified most of
the components and many of the interactions but … the pluralism of causes and effects in
biological networks is better addressed by observing, through quantitative measures,
multiple components simultaneously and by rigorous data integration with mathematical
models" [79]. A potentially promising approach could be the development of statistical
methods for analyzing microbiome data from a biological causal pathway perspective [80,
81]. This analytical methodology is based on structural equations modeling (SEM), a set of
interrelated regression equations with random independent as well as dependent variables
that allow formulation and testing of directional causal pathway hypotheses [82]. Although
widely used in social, economic, and behavioral sciences (e.g. [80, 83–90]), SEM techniques
have been applied only sparingly to ecological data (e.g. [91–93]), despite their original
proposal by the American geneticist Dr. Sewall Wright [94]. Given the increasing
quantitative nature of biological studies and the availability of multimodality genetic,
genomic, proteomic, and other relevant morphological and physiological data, SEM is one
of the most suitable statistical modeling and analysis tools for the study of the biological
networks from a systems biology point of view.
In the example shown in Figure 3, the aim is to study the interactions among host genotype,
gene/protein expression, physiology, morphology, gastro-intestinal microbiome and host
phenotype using structural equation modeling. The composition of the microbiome is treated
as an unknown (latent) variable that can be modeled through multiple observed variables
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using a combination of experimental methods (e.g. different sequencing platforms,
quantitative PCR, and microarrays). Each node with an incoming arrow can be analyzed
through a regression equation with the given node as the response variable and the
originating nodes of the incoming arrow(s) as the independent variables (regressors). If the
node is categorical, such as phenotype, the resulting equation will be a logistic regression. A
numerical node such as microbiome, will lead to a linear regression equation. The path
coefficients (α, β, and λ; Figure 3) are simply the usual regression coefficients. These
regression equations can be analyzed individually, as commonly done, in a sectional
approach. However, a unified simultaneous analysis of this entire equation system is the
optimal solution in terms of the power and accuracy of the resulting statistical inference (K.
Sharpe, PhD thesis, State University of New York at Stony Brook, 2010).
SEMs can be readily extended to handle hierarchical (i.e. longitudinal) datasets using
methods developed for magnetic resonance imaging (MRI) time series data [80]. Moreover,
future work potentially can produce a powerful, unified SEM method that enables the
simultaneous analysis of a pathway network with both continuous (possibly non-normal)
and categorical dependent variables by extending the newly emerging generalized linear
latent and mixed models (GLLAMM; [95]). These methods assess statistical relationships
among complex datasets with mixed data types (i.e. categorical and continuous measures),
for instance allowing for simultaneous correlation of human gene expression and
microbiome data with disease outcomes, such as presence of a particular disease. Although
these methods can not prove assertions about causality, they provide a robust framework for
assessing and potentially rejecting such hypotheses. In the clinical context, the ability to
model the interactions between complex datasets and multi-factorial disease states holds
great promise to both elucidate fundamental features of etiopathogenesis and discover novel
biomarkers of disease onset, severity, and progression.
Concluding remarks and future directions
Rather than discovering exotic new pathogens, the application of microbial metagenomics to
human health has instead provided compelling, though not conclusive, evidence that
disruption of host-microbe mutualism might be central to a variety of pathologies. In these
cases microbial communities, not individual parasitic microorganisms, could play the role of
pathogen [96]. However, other than in exceptional cases we are not likely to observe
disease-associated dysbioses that neatly satisfy all of the criteria that have been proposed to
prove causality [42–44]. Nevertheless, these guidelines provide a logical framework for
assessing disease etiology that reflects the technological and epistemological developments
that have sprung from Koch’s groundwork in clinical microbiology. These investigations
have the potential to identify therapeutic targets that can normalize compositional and
functional microbial alterations that either primarily or secondarily contribute to disease
activity and intensity.
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Figure 1. Possible etiological significance of dysbiosis
Imbalances in microbial communities might be a necessary condition for disease (A) or an
inconsequential result of etiological agents (B) or disease itself (C). Because of the myriad
beneficial services provided by the human-associated microbiota, loss of these functions as a
result of disease development could further exacerbate the severity, duration, or frequency
of disease (D).
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Figure 2. Metagenomic tools for studying host-microbiota interactions in human disease
Bacteria are identified through culture independent analysis of 16S rRNA genes amplified
from surgical specimens by broad-range PCR. Host genotypes and phenotypes are assessed
through analysis of genomic DNA and mRNA of surgical specimens. Together, these data
provide insight into how host factors and enteric microbial communities interact during
development and/or progression of disease. The ultimate goal of these experiments is to use
this knowledge to design, deploy, and monitor novel treatment regimes. Abbreviations: RT,
reverse transcription.
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Figure 3. Incorporating multimodality microbiome measurements
Schematic diagram of potential determinants of human microbiome and host phenotype (e.g.
disease). The central oval (microbiome) depicts an unmeasured latent variable representing
the kinds and quantities of microbes that constitute the microbiome. These are inferred by
various experimental techniques, including Sanger sequencing, 454 pyrosequencing (using
different 16S rRNA primer sets), and quantitative PCR (qPCR). Red arrows denote
influences of host and microbiome on host phenotype whereas blue arrows denote causal
relationships between host factors and microbiome. The relative contributions of these
factors can be modeled using structural equation modeling, as described in the text.
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